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Abstract: Background: Graft-versus-host disease (GVHD) is a major
barrier to successful allogeneic hematopoietic stem-cell transplanta-
tion (HSCT). The chemokine receptor CCR5 appears to play a role in
alloreactivity. We tested whether CCR5 blockade would be safe and
limit GVHD in humans.
Methods: We tested the in vitro effect of the CCR5 antagonist marav-
iroc on lymphocyte function and chemotaxis. We then enrolled 38
high-risk patients in a single-group phase 1 and 2 study of
reduced-intensity allogeneic HSCT that combined maraviroc with
standard GVHD prophylaxis.
Results: Maraviroc inhibited CCR5 internalization and lymphocyte
chemotaxis in vitro without impairing T-cell function or formation
of hematopoietic-cell colonies. In 35 patients who could be evalu-
ated, the cumulative incidence rate (±SE) of grade II to IV acute
GVHD was low at 14.7 ± 6.2% on day 100 and 23.6 ± 7.4% on day
180. Acute liver and gut GVHD were not observed before day 100
and remained uncommon before day 180, resulting in a low cumu-
lative incidence of grade III or IV GVHD on day 180 (5.9 ± 4.1%).
The 1-year rate of death that was not preceded by disease relapse
was 11.7 ± 5.6% without excessive rates of relapse or infection. Serum
from patients receiving maraviroc prevented CCR5 internalization by
CCL5 and blocked T-cell chemotaxis in vitro, providing evidence of
antichemotactic activity.Journal of Hepatology 20
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Chemokines play a major role in the health of the immune sys-
tem. CCR5 is a receptor present at the surface of monocytes/mac-
rophages and activated T-lymphocytes. Its natural ligands
include the CC chemokine ligands (CCL)-3, -4 and -5. CCR5 is a
CD4 coreceptor for the entry of HIV into cells. Maraviroc is a
CCR5 inhibitor that is usually used as an antiretroviral agent in
HIV-infected individuals, in combination with other antiretrovi-
rals. The CCR5-D32 mutation is a 32-base-pair deletion within
the CCR5 coding region that results in a non-functioning receptor.
It was with great interest that we read the recent article by
Reshef et al. in the New England Journal of Medicine, dealing with
the immunomodulatory properties of maraviroc used as an inhib-
itor of T-cell trafﬁcking in graft versus host disease (GVHD) that
frequently compromises allogeneic hematopoietic stem cell
transplantation. During this study, maraviroc prevented in vitro
internalization of CCR5 on effector T-cell subsets and inhibited
T-cell migration following exposure to CCL3 and CCL5. Moreover,
combining this drug with standard GVHD prophylaxis induced a
lower incidence of GVHD, especially affecting the liver and gut, in
the 35 patients evaluated. Interestingly, serum from maraviroc-
treated patients displayed antichemotactic activity in vitro. This
elegant study reinforces previous ﬁndings that highlighted a
lower rate of graft rejection when the CCR5 pathway was inhib-
ited. For example, lower renal transplant rejection rates were
observed in recipients homozygous for the CCR5-D32 allele [1].
Moreover, mice that were either deﬁcient for the membrane
expression of CCR5 or CCL5, or treated with CCR5 monoclonal
antibodies (mAb), presented with less cardiac graft rejection
[2]. Similarly, primates receiving maraviroc demonstrated an
improved survival of heart allografts [3].13 vol. 59 j 613–615
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Fig. 1. Expected effects of the CCR5 antagonist maraviroc. (1) On liver ﬁbrosis: hepatitis C virus (HCV) infection induces inﬂammation and liver injury, leading to the
activation of Kupffer cells and the production of chemokines and cytokines. TGF-b synthesis activates hepatic stellate cells (HSC), inducing liver ﬁbrosis through collagen
production. Fibrosis and inﬂammation due to HCV infection increase the CCR5 expression of cell types involved in ﬁbrosis. The HIV infection of HSC increases the
transformation of HSC into myoﬁbroblasts. Through its envelope glycoprotein, the human immunodeﬁciency virus (HIV) can increase TGF-b synthesis, which in turn leads
to increased HSC activation and HCV replication. HCV enhances the production of chemokines such as CCL5 by endothelial cells, which in turn attracts CD8 T-cell
lymphocytes (CTL) into the liver graft. These speciﬁc CTL produce CCL5. ?Maraviroc could be used to reduce liver ﬁbrosis. (2) On HIV infection: the CCR5 antagonist
maraviroc inhibits the entry of R5 tropic HIV variants into monocytes or activated CD4 T-lymphocytes. (3) On liver graft rejection: T-cells in the recipient recognize
allogeneic major histocompatibility complex (MHC) molecules on the surface of donor Kuppfer cells, leading to CCL3, CCL4, and CCL5 production and CTL recruitment into
the liver graft. ?Maraviroc could be used to decrease the recruitment of CTL and hence inhibit graft rejection.
International HepatologyDespite a lack of data regarding the use of maraviroc in liver-
transplanted HIV/HCV coinfected patients, maraviroc could be
indicated for two reasons: ﬁrstly, to lower liver graft rejection
(LGR) rates in the same way as maraviroc in the context of GVHD
(as presented by Reshef et al.), and secondly, to reduce liver ﬁbro-
sis after liver transplantation (LT), because HCV reinfection can
induce rapid-kinetic liver ﬁbrosis on the liver graft. These two
points are detailed below and in Fig. 1.Expected effects of maraviroc in reducing liver graft rejection
In some patient series, the occurrence of LGR was signiﬁcantly
higher among HIV/HCV-coinfected vs. HCV-monoinfected recipi-
ents [4]. LGR is mainly due to the migration of circulating periph-
eral CD8 T lymphocytes (CTL) which inﬁltrate the liver graft and
are attracted by CCL3, CCL4, and CCL5, leading to Kupffer cell acti-
vation, necrosis and rejection of the graft [5]. In this case, inhib-
iting the CCR5 pathway should reduce the chemotaxis involved in
CTL recruitment into the liver graft (Fig. 1). In support of this
assumption, a CCR5-D32 mutation has been described as a pro-
tective genetic factor against LGR, and one research team pro-
posed minimized immunosuppressive therapy in patients614 Journal of Hepatology 201harboring the homozygous CCR5-D32 mutation [6]. However,
two other studies showed an increase incidence of biliary compli-
cations in CCR5-D32 patients after LT, especially among those
with primary sclerosing cholangitis, but the small number of
homozygous subjects included in that series needs to been taken
into account [7,8]. It is therefore necessary to further study the
long-term management of maraviroc in these patients.Expected effects of maraviroc on reducing ﬁbrosis induced by
HCV reinfection after LT
The natural course of HCV infection in HIV-infected patients dif-
fers signiﬁcantly from that seen in HCV mono-infected patients,
even when effective antiretroviral therapy has been started [9].
LT is now currently indicated in HIV/HCV-coinfected patients,
but the severity of HCV reinfection (as observed in forms involv-
ing ﬁbrosing cholestatic hepatitis) appears to be the principal
challenge [10]. The mechanisms involved in this accelerated pro-
gression remain a subject of debate. The CCR5 pathway is thought
to be involved in liver ﬁbrosis; for example, the administration of
anti-CCR5 mAbs was shown to decrease liver inﬂammation in a
mouse model of liver failure [11]. The mechanisms that are3 vol. 59 j 613–615
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probably involved are shown in Fig. 1. Brieﬂy, injured hepato-
cytes activate Kupffer cells, which in turn secrete pro-inﬂamma-
tory (e.g., IL-6) and ﬁbrosing (e.g., TGF-b) cytokines as well as
inﬂammatory chemokines (e.g., CCL3, CCL4, CCL5), resulting in
the activation of hepatic stellate cells (HSC). HSC-derived myoﬁ-
broblasts secrete collagen and drive ﬁbrosis. Convergent observa-
tions have supported attempts to inhibit CCR5 in HIV/HCV
coinfected patients. Firstly, HCV infection induces inﬂammation
and liver injury, leading to the activation of Kupffer cells, the syn-
thesis of chemokines and TGF-b, and the secretion of CCL5 by vas-
cular endothelial cells. Secondly, intrahepatic lymphocytes from
HCV-infected patients and ﬁbrotic liver express high levels of
CCR5 [11]. Thirdly, HIV envelope glycoprotein directly promotes
HCV replication through an increase in TGF-b secretion by macro-
phages in a CCR5-dependent manner, inducing HSC activation
and collagen synthesis by myoﬁbroblasts [12]. Moreover, HIV-
infected HSCs have been shown to overexpress collagen and
pro-inﬂammatory cytokines, thus increasing ﬁbrogenesis [13].
Lastly, HCV-infected patients who are homozygous for CCR5-
D32 or harbor CCL5 polymorphism may experience attenuated
liver disease with moderate ﬁbrosis [11].
A recent prospective study comparing patients on antiretrovi-
ral therapy that did or did not contain maraviroc demonstrated a
non-progression of liver elastometry and inﬂammatory markers
of ﬁbrosis in serum (i.e., TGF-b, matrix metalloproteinase-2, tis-
sue inhibitor of matrix metalloproteinase-1, APRI score) in the
maraviroc arm vs. the control arm [14].
With respect to tolerance, some authors have already sug-
gested a weak hepatotoxicity of maraviroc, unlike aplaviroc
[15], a CCR5 inhibitor whose development was halted. The pack-
age insert for maraviroc thus includes some speciﬁc warnings
(http://www.emea.europa.eu). It is also necessary to document
in more detail the potential drug-drug interactions that may
occur between maraviroc and immunosuppressive agents.
In conclusion, convergent data argue in favor of administering
maraviroc in HIV/HCV transplanted patients, in order to simulta-
neously reduce LGR and HCV-induced ﬁbrosis. To conﬁrm this
hypothesis, the feasibility of using CCR5 antagonists and poten-
tial pharmacological interactions in this population still need to
be evaluated in the context of prospective studies.Conﬂict of interest
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